Expression Patterns and Clinical Implications of Pdl1 and Dll3 Biomarkers in Small Cell Lung Cancer: Insights for Therapeutic Strategies and Survival Prediction
Kalliopi Domvri(Aristotle University of Thessaloniki), Κonstantinos Porpodis(Aristotle University of Thessaloniki), Theodora Papamitsou(Aristotle University of Thessaloniki), Sofia Karachrysafi(Aristotle University of Thessaloniki), Sofia Lampaki(Aristotle University of Thessaloniki), Styliani Papaemmanouil(Aristotle University of Thessaloniki), Alexey V. Yaremenko(Brigham and Women's Hospital), Apostolos Apostolopoulos(Aristotle University of Thessaloniki), Savvas Petanidis(Aristotle University of Thessaloniki), Nikoleta Pastelli(Aristotle University of Thessaloniki)
Cited by 0
Related Papers
Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects
|Med|2022|222
Nanoparticle-based drug delivery <i>via</i> RBC-hitchhiking for the inhibition of lung metastases growth
|Nanoscale|2018|180
Oral drug delivery platforms for biomedical applications
|Materials Today|2023|123
Fast processes of nanoparticle blood clearance: Comprehensive study
|Journal of Controlled Release|2020|93